Want to see IN:PANACEABIO full AI Analyst Report?
PANACEABIO Stock Chart & Stats
₹440.65
-₹8.10(-1.84%)
At close: 4:00 PM EDT
₹440.65
-₹8.10(-1.84%)
Day’s Range― - ―
52-Week Range₹293.10 - ₹647.50
Previous CloseN/A
Volume125.06K
Average Volume (3M)12.44K
Market Cap
₹25.80B
Enterprise Value₹32.19B
Total Cash (Recent Filing)₹744.00M
Total Debt (Recent Filing)₹236.60M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding61,250,744
10 Day Avg. Volume14,140
30 Day Avg. Volume12,438
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)2.16
Price to Sales (P/S)2.82
P/FCF Ratio-49.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizable, stable equity base provide durable financial flexibility. This supports ongoing capex, R&D, tender participation and strategic partnerships while the company works to stabilise profits and cash flows, reducing refinancing and solvency risk.
Revenue Recovery And GrowthA sustained sales rebound (FY2026 materially higher than FY2023) shows renewed product demand and commercialization traction across formulations and vaccines. Growing top-line provides operating leverage potential and a pathway to durable margin improvement if cost structure is managed.
Operating Cash Flow Turned PositiveReturn to positive operating cash flow is a structural inflection if sustained, indicating core operations can generate cash. This reduces near-term reliance on financing, supports working capital and reinvestment, and is a durable improvement step even while FCF remains negative.
Bears Say
Persistent LossesContinued negative EBIT and net income limit the company’s ability to self-fund growth and erode the economic returns investors expect. Sustained losses force reliance on equity or debt, constrain strategic optionality, and extend the timeline to durable shareholder value creation.
Negative Free Cash Flow Run-rateOngoing negative free cash flow signals persistent cash absorption from investment or working capital. This increases dependence on the balance sheet to fund operations and capex, raising refinancing risk and limiting the ability to sustain long-term investments without improved cash conversion.
Volatile Margins And Weak ReturnsInconsistent margins and erratic profitability indicate structural challenges in translating revenue into returns. This unpredictability complicates capital allocation, undermines the company’s ability to compound equity value over time, and raises execution risk for long-term strategy.
Panacea Biotec Limited News
PANACEABIO FAQ
What was Panacea Biotec Limited’s price range in the past 12 months?
Panacea Biotec Limited lowest stock price was ₹293.10 and its highest was ₹647.50 in the past 12 months.
What is Panacea Biotec Limited’s market cap?
Panacea Biotec Limited’s market cap is ₹25.80B.
When is Panacea Biotec Limited’s upcoming earnings report date?
Panacea Biotec Limited’s upcoming earnings report date is Aug 06, 2026 which is today.
How were Panacea Biotec Limited’s earnings last quarter?
Panacea Biotec Limited released its earnings results on May 30, 2026. The company reported ₹0.08 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.08.
Is Panacea Biotec Limited overvalued?
According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued.
Does Panacea Biotec Limited pay dividends?
Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here
What is Panacea Biotec Limited’s EPS estimate?
Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panacea Biotec Limited have?
Panacea Biotec Limited has 61,250,744 shares outstanding.
What happened to Panacea Biotec Limited’s price movement after its last earnings report?
Panacea Biotec Limited reported an EPS of ₹0.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.399%.
Which hedge fund is a major shareholder of Panacea Biotec Limited?
Currently, no hedge funds are holding shares in IN:PANACEABIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panacea Biotec Limited
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Piramal Pharma Limited
―
Supriya Lifescience Limited
―
Syngene International Ltd.
―